Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma

Bibliographic Details
Main Authors: Kristian T. Andersen, Maja Hinge, Agoston Gyula Szabo, Erik Segel, Tina Ormstrup, Paw C. Holdgaard, Niels Pallisgaard, Gitte Kerndrup, Torben Plesner
Format: Article
Language:English
Published: Atlantis Press 2020-01-01
Series:Clinical Hematology International
Subjects:
Multiple myeloma
Clinical trial
Hematology
First line therapy
Online Access:https://www.atlantis-press.com/article/125932627/view

Internet

https://www.atlantis-press.com/article/125932627/view

Similar Items